NasdaqGM:SMMTBiotechs
Summit Therapeutics (NasdaqGM:SMMT) Reports US$63M Net Loss For Q1 2025
Summit Therapeutics (NasdaqGM:SMMT) reported a net loss of $62.91 million for Q1 2025, an increase from the previous year's loss, alongside a basic and diluted loss per share rising to $0.09. This financial update came as the company saw its stock price increase by 12% over the past week. The market faced a broad 1% decline, influenced by rising bond yields and fiscal concerns, which Summit's stock movement countered. Although no specific news apart from earnings announcements were directly...